Cure Alzheimer's Fund is a non-profit organization dedicated to
funding research with the highest probability of preventing,
slowing or reversing Alzheimer's disease.
For many years, Alzheimer’s disease research was completely
stifled by a lack of funding. Pharmaceutical companies were too
wary of past failures to fund any new drug development. The drug
pipeline was coming up dry, and researchers weren’t encouraged to
think big or bold.
Cure Alzheimer’s Fund has helped change that. They are a 501(c)(3)
nonprofit organization founded in 2004 by three families
frustrated by the slow pace of research. Leveraging their
experience in venture capital and corporate start-ups, the
founders (Henry McCance, Phyllis Rappaport and Jacqui and Jeff
Morby) came together to build a new Alzheimer’s research fund
designed to dramatically accelerate research, make bold bets and
focus exclusively on finding a cure.
Since its founding, Cure Alzheimer’s Fund has contributed more
than $50,000,000 to research, and its funded initiatives have been
responsible for several key breakthroughs—including a potential
treatment recently selected by the National Institutes of Health
(NIH) for its elite “Blueprint” drug discovery program, and the
ground-breaking “Alzheimer's in a Dish” study, which promises to
greatly accelerate drug testing and was reported by The New York
Times as a “giant step forward”.
Cure Alzheimer’s Fund supports some of the best scientific minds
in the field of Alzheimer’s research, and it does so without any
financial gain for its founders or donors. Fully 100 percent of
funds raised by Cure Alzheimer’s Fund go directly to research—the
Board of Directors covers all overhead expenses. .Their Research
Consortium is an all-star team of scientists working at premier
research institutions across the country, regularly conferring
with one another on the progress and impediments in their research
and constantly sharing their data.
Their goal is to stop Alzheimer’s disease through early
prediction, prevention and effective intervention in those
patients who have become symptomatic.
Click Here to visit their website
Very challenging 
